sevelamer rinn phosphate binding medication used treat hyperphosphatemia patients chronic kidney disease taken meals binds dietary phosphate prevents absorption sevelamer invented developed geltex pharmaceuticals sevelamer marketed sanofi brand names renagel sevelamer hydrochloride renvela sevelamer carbonate sevelamer consists polyallylamine crosslinked marketed form sevelamer hydrochloride partial hydrochloride salt present approximately amine hydrochloride sevelamer base amine groups sevelamer become partially protonated intestine interact phosphate ions ionic hydrogen bondingcitation needed sevelamer used management hyperphosphatemia adult patients stage chronic kidney disease ckd hemodialysis efficacy lowering phosphate levels similar calcium acetate without accompanying risk hypercalcemia arterial patients ckd also shown reduce ldl sevelamer therapy contraindicated hypophosphatemia bowel hypophosphatemia sevelamer could exacerbate condition lowering phosphate levels blood could common adverse drug reactions adrs associated use sevelamer include nausea vomiting constipation diarrhea stomach pain heartburn sevelamer significantly reduce serum uric reduction known detrimental effect may helpful patients gout sevelamer able sequester advanced glycation end products ages gut preventing absorption blood ages contribute oxidative stress damage cells like beta cells produce insulin pancreas vlassara uribarri explain review ages may explain sevelamer calcium carbonate phosphate binder sequester ages shown lower ages blood well oxidative stress inflammatory httpsenwikipediaorgwikisevelamer